Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, manufacture, and sale of oral, controlled-release products and generic pharmaceuticals. The company operates through two segments: Abbreviated New Drug Applications (ANDAs) for generic drugs and New Drug Applications (NDAs) for branded drugs. Its product portfolio includes generic oral dose pharmaceuticals such as Phentermine HCl 37.5mg tablets and 15mg and 30mg capsules for bariatric treatment under the Adipex-P brand, as well as Phendimetrazine Tartrate 35mg tablets (Bontril), Naltrexone HCl 50mg tablets (Revia) for pain, Isradipine capsules for cardiovascular diseases, and Trimipramine Maleate capsules (Surmontil) for depression. The company also markets Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate immediate-release tablets (Adderall) and extended-release capsules (Adderall XR) for central nervous system disorders, along with Dantrolene Sodium capsules (Dantrium) as a muscle relaxant, SequestOX (an immediate-release Oxycodone with sequestered Naltrexone), Loxapine Succinate capsules (Loxapine) for antipsychotic use, and Acetaminophen and Codeine Phosphate for pain management.

Elite Pharmaceuticals, Inc. is traded on the OTC Markets OTCQB exchange under the ticker symbol ELTP. The OTCQB is a venture market designed for early-stage and developing U.S. and international companies. All trading for ELTP is conducted in U.S. Dollars (USD), which is the company's reporting currency. As an over-the-counter listing, the stock is not listed on major exchanges like the NYSE or Nasdaq, but it provides investors with access to the company's shares through broker-dealers. The OTCQB requires companies to meet certain financial standards and undergo annual verification, offering a regulated trading environment for emerging growth companies.

Elite Pharmaceuticals operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, production, and marketing of pharmaceutical drugs, with a focus on both generic versions of existing medications and specialty branded products. As a specialty generic drug manufacturer, Elite targets niche therapeutic areas such as bariatrics (weight management), central nervous system disorders, pain management, cardiovascular diseases, and antipsychotic treatments. The company's portfolio includes both immediate-release and extended-release formulations, leveraging controlled-release technology to differentiate its products in the generic pharmaceutical market.

Elite Pharmaceuticals, Inc. is headquartered in the United States and primarily serves the U.S. pharmaceutical market. As a domestic company, it focuses on developing, manufacturing, and distributing its products within the United States, where it markets its generic and branded pharmaceuticals to wholesalers, distributors, and retail pharmacies. The company's operations are structured to comply with U.S. Food and Drug Administration (FDA) regulations, and its product portfolio includes drugs approved under Abbreviated New Drug Applications (ANDAs) and New Drug Applications (NDAs). While the company's summary does not specify international operations, its core market is the United States, where it competes in the specialty generic pharmaceutical segment.

Elite Pharmaceuticals generates revenue through the development, manufacture, and sale of oral, controlled-release generic and branded pharmaceutical products. The company's business model is divided into two segments: generic pharmaceuticals under Abbreviated New Drug Applications (ANDAs) and branded pharmaceuticals under New Drug Applications (NDAs). Revenue is derived from product sales to customers such as wholesalers, distributors, and pharmacies. Key revenue-generating products include Phentermine HCl (Adipex-P) and Phendimetrazine Tartrate (Bontril) for bariatrics, Naltrexone HCl (Revia) for pain, Isradipine for cardiovascular conditions, Trimipramine Maleate (Surmontil) for depression, and various formulations of amphetamine salts (Adderall and Adderall XR) for central nervous system disorders. Additionally, the company markets Dantrolene Sodium (Dantrium), SequestOX (Oxycodone with Naltrexone), Loxapine Succinate (Loxapine), and Acetaminophen with Codeine Phosphate. By focusing on niche therapeutic areas and controlled-release technologies, Elite aims to capture market share in the specialty generic pharmaceutical space.